In Toronto, Two International Leaders Share One Goal: Slow or Halt the Progression of Alzheimer’s Disease with the Launch of Phase 3 Clinical Trials
Professor Claude Wischik, Executive Chairman of TauRx Therapeutics and Dr. Sharon Cohen, Medical Director of the Toronto Memory Program Announce the Canadian Launch of Pivotal Alzheimer’s Research
Clinical trials get under way in the UK with a second‐generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s
Dundee Corporation maintains 5% stake in company developing a revolutionary treatment for Alzheimer’s Disease.
Major Conference in Poland will Spotlight TauRx Therapeutics as an Example of International Entrepreneurial Success in Life Science
TauRx Pharmaceuticals receives $111.8m commitment from Genting to prepare for Market Leadership in Alzheimer’s
Professor Claude Wischik found that the underlying pathology of Alzheimer’s known as Tau tangles is present in the brain up to 30 years before clinical symptoms develop and that the presence of this pathology is highly correlated with disease progression.
Professor Claude Wischik and Dr. Jiri Hardlund held an important online press conference webinar for ALL to attend at the 5th Clinical Trials Conference on Alzheimer's Disease (CTAD).
Phase 3 clinical trial begins in mild to moderate Alzheimer's Disease with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer's.
Phase 3 clinical trial begins in early form of dementia
US patent granted: Patent for TauRx’s next generation Tau Aggregation Inhibitor compound granted extensively